HEADER SUGAR BINDING PROTEIN 18-AUG-11 2LI1 TITLE MONO-O-GALNAC GLYCOSYLATED MUCIN SEQUENCE BASED ON MUC2 MUCIN TITLE 2 GLYCOPROTEIN TANDEM REPEAT COMPND MOL_ID: 1; COMPND 2 MOLECULE: MUC2 MUCIN DOMAIN PEPTIDE; COMPND 3 CHAIN: A; COMPND 4 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: SYNTHETIC CONSTRUCT; SOURCE 4 ORGANISM_TAXID: 32630; SOURCE 5 OTHER_DETAILS: SYNTHESIZED VIA SOLID PHASE PEPTIDE SYNTHESIS KEYWDS GLYCOSYLATION, TN ANTIGEN, SUGAR BINDING PROTEIN EXPDTA SOLUTION NMR NUMMDL 27 AUTHOR A.BORGERT,J.HEIMBURG-MOLINARO,Y.LASANAJAK,T.JU,M.LIU,P.THOMPSON, AUTHOR 2 G.RAGUPATHI,G.BARANY,R.CUMMINGS,D.SMITH,D.LIVE REVDAT 3 29-JUL-20 2LI1 1 COMPND SOURCE REMARK HETNAM REVDAT 3 2 1 LINK SITE ATOM REVDAT 2 27-JUN-12 2LI1 1 JRNL REVDAT 1 04-APR-12 2LI1 0 JRNL AUTH A.BORGERT,J.HEIMBURG-MOLINARO,X.SONG,Y.LASANAJAK,T.JU,M.LIU, JRNL AUTH 2 P.THOMPSON,G.RAGUPATHI,G.BARANY,D.F.SMITH,R.D.CUMMINGS, JRNL AUTH 3 D.LIVE JRNL TITL DECIPHERING STRUCTURAL ELEMENTS OF MUCIN GLYCOPROTEIN JRNL TITL 2 RECOGNITION. JRNL REF ACS CHEM.BIOL. V. 7 1031 2012 JRNL REFN ISSN 1554-8929 JRNL PMID 22444368 JRNL DOI 10.1021/CB300076S REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS, XPLOR-NIH REMARK 3 AUTHORS : BRUNGER A. T. ET.AL. (CNS), SCHWIETERS, KUSZEWSKI, REMARK 3 TJANDRA AND CLORE (XPLOR-NIH) REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2LI1 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 26-AUG-11. REMARK 100 THE DEPOSITION ID IS D_1000102409. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 288 REMARK 210 PH : 4.5 REMARK 210 IONIC STRENGTH : NULL REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 2-10 MM MUC2 MUCIN DOMAIN REMARK 210 PEPTIDE, 2-10 MM SUGAR (N-ACETYL-2-DEOXY-2-AMINO-GALACTOSE), 90% REMARK 210 H2O/10% D2O; 2-10 MM MUC2 MUCIN DOMAIN PEPTIDE, 2-10 MM SUGAR (N- REMARK 210 ACETYL-2-DEOXY-2-AMINO-GALACTOSE), 100% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-1H NOESY; 3D TOCSY-NOESY; REMARK 210 2D 1H-15N HSQC; 2D 1H-13C HSQC; REMARK 210 2D 1H-1H TOCSY; 2D 1H-1H COSY; REMARK 210 2D 1H-13C HMBC REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ; 800 MHZ; 900 MHZ REMARK 210 SPECTROMETER MODEL : INOVA REMARK 210 SPECTROMETER MANUFACTURER : VARIAN REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NULL REMARK 210 METHOD USED : TORSION SPACE SIMULATED REMARK 210 ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 100 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 27 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LEAST REMARK 210 RESTRAINT VIOLATIONS REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 THE MODIFIED SEQUENCE PTTTPLK FRAGMENT WAS CHOSEN BECAUSE IT WAS REMARK 400 RELEVANT TO STRUCTURE/FUNCTION ANALYSIS OF POST TRANSLATIONAL REMARK 400 GLYCOSYLATION OF MUC2, FOR WHICH IT WAS USED AS A MODEL SUBSTRATE. REMARK 400 STUDIES ON IT AND ON O-GALNAC GLYCOSYLATED FORMS HAD BEEN CARRIED REMARK 400 OUT USING SEVERAL POLYPEPTIDE GALNAC TRANSFERASE ISOFORMS. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 THR A 3 35.29 -152.90 REMARK 500 1 PRO A 6 101.78 -44.62 REMARK 500 2 THR A 3 35.08 -152.90 REMARK 500 2 PRO A 6 90.44 -44.53 REMARK 500 3 THR A 3 48.34 -153.30 REMARK 500 3 PRO A 6 91.75 -38.16 REMARK 500 3 LEU A 7 113.75 -163.82 REMARK 500 4 THR A 3 39.39 -153.13 REMARK 500 4 THR A 5 64.93 -154.38 REMARK 500 4 PRO A 6 162.44 -44.66 REMARK 500 5 THR A 3 42.52 -153.21 REMARK 500 5 THR A 5 73.33 -154.41 REMARK 500 6 THR A 3 35.34 -153.19 REMARK 500 6 PRO A 6 86.55 -44.63 REMARK 500 7 THR A 3 49.58 -153.58 REMARK 500 7 PRO A 6 105.72 -44.74 REMARK 500 7 LEU A 7 116.80 -163.33 REMARK 500 8 THR A 3 45.22 -153.23 REMARK 500 8 THR A 5 66.81 -154.40 REMARK 500 8 PRO A 6 165.65 -44.67 REMARK 500 9 THR A 3 40.26 -153.18 REMARK 500 9 PRO A 6 74.06 -44.64 REMARK 500 9 LEU A 7 24.52 -76.33 REMARK 500 10 THR A 3 35.17 -152.89 REMARK 500 10 LEU A 7 97.35 -163.21 REMARK 500 11 THR A 3 35.05 -152.95 REMARK 500 11 PRO A 6 103.26 -44.67 REMARK 500 12 THR A 3 35.16 -152.88 REMARK 500 12 PRO A 6 86.40 -44.68 REMARK 500 13 THR A 3 39.98 -153.21 REMARK 500 13 PRO A 6 103.02 -44.59 REMARK 500 14 THR A 3 39.66 -153.16 REMARK 500 14 PRO A 6 103.77 -44.55 REMARK 500 14 LEU A 7 97.82 -163.22 REMARK 500 15 THR A 3 41.58 -153.21 REMARK 500 15 PRO A 6 98.23 -44.64 REMARK 500 16 THR A 3 39.68 -153.14 REMARK 500 16 PRO A 6 100.32 -44.75 REMARK 500 16 LEU A 7 22.48 -75.67 REMARK 500 17 THR A 3 46.21 -153.08 REMARK 500 18 THR A 3 35.82 -153.06 REMARK 500 18 PRO A 6 98.02 -44.68 REMARK 500 19 THR A 3 38.46 -153.16 REMARK 500 19 PRO A 6 102.15 -44.60 REMARK 500 20 THR A 3 38.17 -152.92 REMARK 500 20 PRO A 6 107.98 -44.57 REMARK 500 21 THR A 3 35.26 -153.15 REMARK 500 21 THR A 5 66.33 -154.35 REMARK 500 21 LEU A 7 26.69 -75.73 REMARK 500 22 THR A 3 40.90 -153.21 REMARK 500 REMARK 500 THIS ENTRY HAS 64 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 17874 RELATED DB: BMRB REMARK 900 RELATED ID: 2LHV RELATED DB: PDB REMARK 900 RELATED ID: 2LHW RELATED DB: PDB REMARK 900 RELATED ID: 2LHX RELATED DB: PDB REMARK 900 RELATED ID: 2LHY RELATED DB: PDB REMARK 900 RELATED ID: 2LHZ RELATED DB: PDB REMARK 900 RELATED ID: 2LI0 RELATED DB: PDB REMARK 900 RELATED ID: 2LI2 RELATED DB: PDB REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE SEQUENCE PTTTP IS PART OF THE MUC2 MUCIN REPEAT POLYPEPTIDE REMARK 999 PTTTPITTTTTVTPTPTPTGTQT. DBREF 2LI1 A 1 9 PDB 2LI1 2LI1 1 9 SEQRES 1 A 9 ACE PRO THR THR THR PRO LEU LYS NH2 MODRES 2LI1 THR A 4 THR GLYCOSYLATION SITE HET ACE A 1 6 HET NH2 A 9 3 HET A2G A 10 28 HETNAM ACE ACETYL GROUP HETNAM NH2 AMINO GROUP HETNAM A2G 2-ACETAMIDO-2-DEOXY-ALPHA-D-GALACTOPYRANOSE FORMUL 1 ACE C2 H4 O FORMUL 1 NH2 H2 N FORMUL 2 A2G C8 H15 N O6 LINK C ACE A 1 N PRO A 2 1555 1555 1.31 LINK OG1 THR A 4 C1 A2G A 10 1555 1555 1.41 LINK C LYS A 8 N NH2 A 9 1555 1555 1.30 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL ENDMDL MASTER 162 0 3 0 0 0 0 6 0 0 0 1 END